PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial

• Published in: The journal of clinical endocrinology and metabolism Vol. 101; no. 4; pp. 1525 - 1534
• Main Authors: Fiore, Daniela, Gianfrilli, Daniele, Giannetta, Elisa, Galea, Nicola, Panio, Giuseppe, di Dato, Carla, Pofi, Riccardo, Pozza, Carlotta, Sbardella, Emilia, Carbone, Iacopo, Naro, Fabio, Lenzi, Andrea, Venneri, Mary A., Isidori, Andrea M.
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 01.04.2016; Copyright by The Endocrine Society
• Subjects: Adipose tissue; Adiposity - drug effects; Adiposity - genetics; Adult; Aged; Animal models; Animals; Biopsy; Body fat; Cardiomyocytes; Cardiovascular diseases; Cell culture; Cyclic Nucleotide Phosphodiesterases, Type 5 - chemistry; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - physiopathology; DNA microarrays; Double-Blind Method; Flow Cytometry; Gene expression; Heart; Humans; Inflammation; Magnetic resonance imaging; Male; Mice; Mice, Obese; MicroRNAs; MicroRNAs - genetics; Middle Aged; miRNA; Obesity, Abdominal - drug therapy; Obesity, Abdominal - metabolism; Obesity, Abdominal - pathology; Phosphodiesterase 5 Inhibitors - pharmacology; Placebos; Real-Time Polymerase Chain Reaction; Sildenafil; Sildenafil Citrate - pharmacology; SIRT1 protein; Sirtuin 1 - genetics; Sirtuin 1 - metabolism

Context:Visceral adiposity plays a significant role in cardiovascular risk. PDE5 inhibitors (PDE5i) can improve cardiac function and insulin sensitivity in type 2 diabetes patients.Objective:To investigate whether PDE5i affect visceral adipose tissue (VAT), specifically epicardial fat (epicardial ad...